Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $26

Benzinga Newsdesk www.benzinga.com Negative 56.4%

Neg 56.4% Neu 0% Pos 0%

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $52 to $26.